Monitor the actual closing amount — with no minimum, proceeds may fall far short of $7M, leaving the company still cash-constrained. Watch for Nasdaq delisting risk if the stock fails to maintain $1.00 bid price; the company may need another reverse split. The massive warrant overhang (25.8M Series B warrants at $1.2046, 4.0M Series C at $2.50, plus up to 40.7M new Series D warrants) will pressure the stock for years.
Executive Summary
Sunshine Biopharma Inc. filed an S-1 registration statement for a best-efforts offering of up to 10,180,337 Common Units (each consisting of one share of common stock and two Series D Warrants) at an assumed price of $0.6876 per unit, targeting up to $7.0 million in gross proceeds. The company, which markets 60 generic drugs in Canada via Nora Pharma and conducts early-stage oncology/antiviral R&D, had only $13.7 million in cash as of June 30, 2026, and faces Nasdaq minimum bid price non-compliance. The offering is highly dilutive (pro forma shares outstanding would increase from 4.3M to 14.5M) and has no minimum closing amount, creating significant uncertainty about actual proceeds.
Key Financial Metrics
Key Facts
- Offering of up to 10,180,337 Common Units at $0.6876/unit, each unit = 1 share + 2 Series D Warrants (exercise price $0.6876, 5-year term)
- Up to 10,180,337 Pre-Funded Units also offered for investors exceeding 4.99%/9.99% beneficial ownership limits
- Net proceeds estimated at ~$6.0M after placement agent fees (7%) and expenses (~$340k)
- Pro forma shares outstanding would jump from 4,310,301 to 14,490,638 — a 236% increase
- Cash and cash equivalents were $13.7M as of June 30, 2026; pro forma as-adjusted cash would be $22.0M
- No minimum offering amount — actual proceeds could be substantially less than $7.0M
- Stock trades below $1.00 Nasdaq minimum bid price; company is subject to immediate delisting risk through June 2027
- CEO Dr. Steve Slilaty holds 130,000 Series B Preferred shares (100% of series) giving ~97% voting control
- Series D Warrants include a Share Combination Event adjustment that could reduce exercise price to as low as $0.3438, subject to stockholder approval
- Placement agent Aegis Capital Corp. receives a 30-month right of first refusal on future financings
Financial Impact
Up to $7.0M gross / ~$6.0M net proceeds; potential dilution of 236% in share count; no revenue or earnings data in filing
Risk Factors
- Nasdaq delisting risk — stock trading below $1.00 minimum bid price; company subject to immediate delisting notice through June 2027
- No minimum offering amount — actual proceeds may be far below $7.0M, insufficient for working capital needs
- Massive dilution — pro forma shares increase 236% even before warrant exercises; full warrant exercise could add up to 40.7M more shares
- CEO controls ~97% voting power via Series B Preferred, creating governance risk for minority holders
- Pre-revenue proprietary drug pipeline (K1.1 mRNA, SBFM-PL4) with no near-term commercialization prospects
- Warrant overhang from prior Series B (25.8M at $1.2046) and Series C (4.0M at $2.50) warrants — all out of the money at current price
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001683168-26-007581 |
| Document: sunshine_ex1021.htm | 0001683168-26-007581 |
| Document: sunshine_ex1020.htm | 0001683168-26-007581 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | — |
Oct 13, 2026 12d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | — |
Oct 9, 2026 16d ago | 8-K | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | — |
Oct 9, 2026 16d ago | 424B4 | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | — |
Oct 8, 2026 18d ago | EFFECT | $0.4300 $0.2300 | ▲ +46.51% | ▲ +46.24% | — |
Oct 5, 2026 20d ago | SC 13G/A | $0.3979 $0.2363 | ▲ +40.61% | ▲ +40.47% | — |
Oct 2, 2026 23d ago | S-1 | $0.4201 $0.3020 | ▲ +28.11% | ▲ +28.53% | — |
Sep 9, 2026 6w ago | EFFECT | $1.12 $1.04 | ▲ +7.59% | ▲ +7.26% | — |
Aug 28, 2026 8w ago | 8-K | $1.12 $1.15 | ▲ +2.68% | ▲ +2.82% | — |
Aug 3, 2026 12w ago | 8-K | $1.17 $1.22 | ▲ +4.27% | ▲ +2.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers